These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32468878)

  • 1. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
    Chen E; Pei R
    J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
    Sydor S; Jafoui S; Wingerter L; Swoboda S; Mertens JC; Gerken G; Canbay A; Paul A; Fingas CD
    World J Gastroenterol; 2017 Jun; 23(22):4007-4015. PubMed ID: 28652654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
    Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
    Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
    Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
    Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
    Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
    Spender LC; Inman GJ
    Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
    Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
    Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
    Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
    Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
    Ergul M; Bakar-Ates F
    Chem Biol Interact; 2020 Dec; 332():109288. PubMed ID: 33075310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
    Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
    Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.
    Thrum S; Lorenz J; Mössner J; Wiedmann M
    Anticancer Res; 2011 Oct; 31(10):3289-99. PubMed ID: 21965739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
    J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
    Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
    Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
    Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines.
    Riantana H; Waenphimai O; Mahalapbutr P; Karnchanapandh K; Vaeteewoottacharn K; Wongkham S; Sawanyawisuth K
    Pathol Res Pract; 2023 Aug; 248():154678. PubMed ID: 37454493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.